Houston Methodist Hospital

NuVasive Showcases Latest Innovation in Virtual Global Event

Retrieved on: 
星期四, 十一月 17, 2022
SAN, Elective surgery, Deformity, SPS, News, Spine, University, Surgeon, Software, Legacy Health, Standard of care, Multimedia, Patient, Sacrum, Hospital, World of McIntosh Experience Center, Prone position, NuVasive, Houston Methodist Hospital, MR, Decompression, Renewable energy, Medicine, Medical device, Northwestern Medicine, EU, Pulse, X360, Commercial software

SAN DIEGO, Nov. 17, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, held a virtual event yesterday showcasing the Company's latest innovation across its market-leading 360 portfolios.

Key Points: 
  • SAN DIEGO, Nov. 17, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, held a virtual event yesterday showcasing the Company's latest innovation across its market-leading 360 portfolios.
  • NuVasivedelivered a one-hour, virtual global event sharing how the Company's portfolios are transforming surgery, advancing care, and changing patient lives.
  • Highlights of the NuVasive Innovation Event by portfolio:
    C360 : Dr. Paul Holman, Houston Methodist Hospital, and Dr. Michael Wang, University of Miami Health System, discussed the future of cervical spine surgery with enabling technologies.
  • NuVasive, Inc.(NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives.

Clinicians at 2022 AVA Scientific Meeting Discuss Observed CLABSI-Reductions With SecurePortIV® Adhesive

Retrieved on: 
星期二, 十一月 8, 2022
GLOBE, Adult, Baylor Scott & White Medical Center – Temple, Ball Memorial Hospital, Association, MSN, Cabell Huntington Hospital, CNL, RN, PICC, CLABSI, Infant, Standard of care, Froedtert Hospital, CEO, Central, Houston Methodist Hospital, Medicine

MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- At the 2022 Association for Vascular Access ("AVA") Annual Scientific Meeting, clinicians reported statistically significant reductions in dressing changes and Central Line-Associated Bloodstream Infections ("CLABSI") as a result of utilizing Adhezion Biomedical's SecurePortIV Catheter Securement Adhesive.

Key Points: 
  • MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- At the 2022 Association for Vascular Access ("AVA") Annual Scientific Meeting, clinicians reported statistically significant reductions in dressing changes and Central Line-Associated Bloodstream Infections ("CLABSI") as a result of utilizing Adhezion Biomedical's SecurePortIV Catheter Securement Adhesive.
  • These findings were presented by clinicians representing seven separate institutions throughout the conference.
  • Study results were presented by clinicians at Baylor Scott and White Health System (TX), Carilion Children's Hospital(VA), Froedtert Hospital (WI), Ball Memorial Hospital (IN), Houston Methodist Hospital (TX) and Cabell Huntington Hospital (WV).
  • The demand for SecurePortIV adhesive continues to grow rapidly since it was recognized as a Standard of Care for vascular access securement by the Infusion Nurses Society in 2021.

Aymen H. Rashid, MD is recognized by Continental Who's Who

Retrieved on: 
星期三, 十月 26, 2022
Birth, Scoliosis, Human, Skull, Scoliosis Research Society, Sacrum, Degenerative disease, Infection, MVHS, State University of New York Upstate Medical University, Neoplasm, Patient, Augmented fifth, Hospital, Mentorship, Indian Medical Association, Back pain, Johns Hopkins University, North American Spine Society, Spine, Elective surgery, Goal, Johns Hopkins School of Medicine, Orthopedic surgery, American Medical Association, Medicine, American Academy, Houston Methodist Hospital, Continental, School, Dentistry, MD

UTICA, N.Y., Oct. 26, 2022 /PRNewswire/ -- Aymen H. Rashid, MD, is being recognized by Continental Who's Who as a Distinguished Orthopedic Surgeon in the Medical field, acknowledging his outstanding work with MVHS Orthopedic Group.

Key Points: 
  • UTICA, N.Y., Oct. 26, 2022 /PRNewswire/ -- Aymen H. Rashid, MD, is being recognized by Continental Who's Who as a Distinguished Orthopedic Surgeon in the Medical field, acknowledging his outstanding work with MVHS Orthopedic Group.
  • Prior to joining MVHS, he served as the Director of the Ortho Spine Center at Slocum Dickson Medical Group.
  • MVHS Orthopedic Group is the local resource for the most up-to-date procedures and treatments addressing various orthopedic conditions.
  • In light of this recognition, the doctor wishes to acknowledge his mentors: William Lavell, MD, and Chris Myer, MD.

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

Retrieved on: 
星期一, 十月 24, 2022
Gene expression, Administration, Time, Houston, Disease, RNA transfection, Sebastiano, Efficiency, Ophthalmology, Houston Methodist Hospital, Dermatology, Patient, ERA, RNA, Research, Tissue, Osteoarthritis, Electroporation, Technology, Cancer, CAR, New, CST, Patient safety, Safety, Epigenome, Ageing, Epigenetics, Vaccine, Pharmaceutical industry, Medical imaging

The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.

Key Points: 
  • The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.
  • "ERA provides the opportunity for enhanced dose management and optimization with the ability to personalize dosing to maximize efficiency without compromising patient safety.
  • "We found eTurna preserves T-cell health and functionality better than electroporation, facilitating greater cell viability and production during CAR T manufacturing," he said.
  • Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems.

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

Retrieved on: 
星期一, 十月 24, 2022
Gene expression, Administration, Time, Houston, Disease, RNA transfection, Sebastiano, Efficiency, Ophthalmology, Houston Methodist Hospital, Dermatology, Patient, ERA, RNA, Research, Tissue, Osteoarthritis, Electroporation, Technology, Cancer, CAR, New, CST, Patient safety, Safety, Epigenome, Ageing, Epigenetics, Vaccine, Pharmaceutical industry, Medical imaging

The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.

Key Points: 
  • The findings promise to help reduce the cost of T-cell therapies and make them more accessible to cancer patients.
  • "ERA provides the opportunity for enhanced dose management and optimization with the ability to personalize dosing to maximize efficiency without compromising patient safety.
  • "We found eTurna preserves T-cell health and functionality better than electroporation, facilitating greater cell viability and production during CAR T manufacturing," he said.
  • Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems.

Global Convalescent Plasma Therapy Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 17, 2022
Health, General Health, Infection, Journal of Medical Virology, Someren-Eind, GSK, Disease, IND, Immunoglobulin G, Immunoglobulin M, Laboratory, Virology, Severe acute respiratory syndrome coronavirus 2, Immunity, Antibody, Patient, Hospital, CPT, RNA, Mortality, Coronavirus, Collection, MERS, US, Application, Houston Methodist Hospital, Safety, Branches of microbiology, Immunoglobulin A, Journal, CDSCO, Plasma, Mucous membrane, FDA, COVID-19, Pharmaceutical industry

The "Convalescent Plasma Therapy Global Market Report 2022, By Application, By End-Users, By Antibody type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Convalescent Plasma Therapy Global Market Report 2022, By Application, By End-Users, By Antibody type" report has been added to ResearchAndMarkets.com's offering.
  • In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate.
  • The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market.
  • The convalescent plasma therapy market consists of sales of convalescent plasma obtained from patients who have recovered from an infection.

OMRON Healthcare Issues National Health Alert for Cold & Flu Season and Potential COVID Variants, Warning of Increased Heart Attack and Stroke Risk

Retrieved on: 
星期四, 十月 6, 2022
Zero, Time, Insurance, Medicaid, Hypertension, Risk, Stroke, ScienceDaily, Infection, COVID, Family, Degenerative disease, United States National Library of Medicine, Research, Health education, Blood pressure, Multimedia, Technology, Center, Immune system, National library, Health, CEO, Houston Methodist Hospital, Journal, Meta-analysis, Journal of the American College of Cardiology, American College, TENS, COVID-19, OMRON, Pharmaceutical industry, Animal, Dietary supplement, Medical device, Vaccine

HOFFMAN ESTATES, Ill., Oct. 6, 2022 /PRNewswire/ -- As the U.S. enters another cold and flu season along with the potential of rising infections from COVID variants, global heart health leader OMRON Healthcare is issuing a national health alert warning of increased risk for those with high blood pressure and calling for regular blood pressure monitoring and active management of hypertension. Clinical data shows high blood pressure contributing to complications from COVID1 and could factor into "long COVID" symptoms.2 Research also shows high blood pressure as an aggravating chronic condition for complications from seasonal flu – a 2018 study found that the risk of having a heart attack was six times higher within a week of a flu infection.3

Key Points: 
  • "High blood pressure is a national health crisis affecting 116 million U.S. adults and the risks of heart attack and stroke are even higher during cold and flu season.
  • Monitor your blood pressure weekly or daily to understand your heart health, especially during cold and flu season and times of heightened risk of COVID transmission.
  • Talk to your doctor and take action to manage your condition and reduce your risk of heart attack and stroke.
  • Increased cardiac event risk can be present even after you no longer feel symptoms from COVID or flu infection.

MAI Capital Management Taps Colter Lewis to Grow Its National Wealth Management Platform

Retrieved on: 
星期四, 九月 8, 2022
Banking, Professional Services, Finance, Partnership, DePelchin Children's Center, Houston Methodist Hospital, Technology, Cynthia Woods Mitchell Pavilion, Solution, MAI, Central Texas Regional Mobility Authority, Investment, Geode Capital Management, Athlete, Leadership, Abilene Christian University, LLC, Acquisition, Wealth management, Growth, Chartered financial consultant, Industry, Financial services, Northern Trust

Lewis will be responsible for overseeing MAIs wealth management platform and expanding the firms national presence, including key markets in the southwest.

Key Points: 
  • Lewis will be responsible for overseeing MAIs wealth management platform and expanding the firms national presence, including key markets in the southwest.
  • Our team remains focused on expanding our reach and optimizing organic and inorganic growth, while building a leading, national wealth management firm.
  • Lewis brings over 25 years of industry experience in investments, wealth management and private banking to his new role with MAI.
  • Colter has a track record of building extraordinary wealth management teams, and were excited to leverage his leadership to reach our goal of becoming a national wealth management platform.

10th Annual Oliver Wyman Health Innovation Summit Explores 'New Norms, New Expectations' for Healthcare

Retrieved on: 
星期三, 九月 7, 2022
People, Metaverse, Health care, Technology, Solution, View, News, Health, Science, Risk management, Twitter, Summit, AbbVie, VP, Workforce, City, Time, List of life sciences, Industry, Social media, Oliver Wyman, Regular-Irregular, Houston Methodist Hospital, Bellingcat: Truth in a Post-Truth World, Citizenship, Information Trust Institute, Second City, LinkedIn, New People, Gold, Market share, Multimedia, NYSE, National Human Genome Research Institute, EVP, New-collar worker, Blog, MMC, Oliver, Interview, Marsh McLennan, Public relations, Creative industries, Online shopping, Calibration

More than 300 senior healthcare leaders from 150 companies committed to transforming healthcare will convene in Chicago on Sept. 1921, 2022, to discuss the industry's future at the 10th annual Oliver Wyman Health Innovation Summit.

Key Points: 
  • More than 300 senior healthcare leaders from 150 companies committed to transforming healthcare will convene in Chicago on Sept. 1921, 2022, to discuss the industry's future at the 10th annual Oliver Wyman Health Innovation Summit.
  • Individuals not attending the event can access real-time insights and perspectives through Oliver Wyman's social media channels, including Twitter via @OliverWyman , @ OWHealthEditor and LinkedIn via Oliver Wyman and Oliver Wyman Health .
  • Oliver Wyman launched the Health Innovation Center (OWHIC) in 2011 to accelerate health market transformation.
  • For the latest on the business of transforming healthcare, visit the Oliver Wyman Health digital platform at health.oliverwyman.com and follow us on Twitter @OWHealthEditor .

New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging

Retrieved on: 
星期二, 九月 6, 2022
American Association of Physicists in Medicine, Inflammation, PET, Guideline, ASNC, American Association, Master of Science, SPECT/CT, OnDemand, Cross, Solution, Houston Methodist Hospital, Society, Table, Molecular imaging, Physician, Journal of Nuclear Cardiology, MPI, CACS, Society of Cardiovascular Computed Tomography, Organization, Journal, Physicist, Health, American Society of Nuclear Cardiology, Collaboration, Atherosclerosis, SCCT, PET/CT, Competence, Hibernation, Knowledge, AAPM, Coronary artery disease, Hardware, Society of Nuclear Medicine and Molecular Imaging, Cardiology, Patient, SNMMI, Medical imaging, Medicine, Software, MD

FAIRFAX, Va., September 06, 2022 /PRNewswire-PRWeb/ -- The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to answer cardiac imagers' questions about SPECT/CT and PET/CT imaging with attenuation correction, localization of radiotracer uptake and coronary artery calcium scoring (CACS). In a new multisociety guideline published today in the Journal of Nuclear Cardiology, the organizations recommend training and competency requirements for imaging physicians and technologists; describe models for collaborative, cross-specialty study interpretation and reporting; and suggest solutions for the preauthorization and reimbursement challenges that some labs have faced with hybrid imaging in nuclear cardiology.

Key Points: 
  • "Assessing atherosclerosis burden in hybrid imaging improves the diagnostic accuracy of MPI studies and help clinicians identify high-risk patients and treat them accordingly.
  • The question is not whether today's cardiac imaging labs should adopt hybrid imaging but rather how to adapt their labs for the routine use of SPECT/CT and PET/CT.
  • Imaging teams will find the new guideline is a blueprint for modernizing their labs for the delivery of hybrid nuclear-CT imaging.
  • ASNC's Hybrid Imaging Symposium will be delivered in two parts:
    Part 1 is currently available OnDemand on the ASNC2022 online meeting platform.